External hypofractionated whole-breast radiotherapy: now where does accelerated partial breast irradiation stand?

Simple item page
dc.contributor.authorMunshi, Anusheelen_US
dc.date.accessioned2007-10-14en_US
dc.date.accessioned2009-06-01T16:27:10Z
dc.date.available2007-10-14en_US
dc.date.available2009-06-01T16:27:10Z
dc.date.issued2007-10-14en_US
dc.description32 references.en_US
dc.description.abstractBreast-conserving therapy (BCT) has emerged as a viable option for suitable breast cancer patients who are desirous of preserving the breast. The major advantage of BCT is the good cosmetic outcome with disease-free and overall survival similar to mastectomy. In this article, I have compared two emerging modalities for treating a preserved breast with radiotherapy. These two techniques in breast cancer - accelerated partial breast irradiation (APBI) and hypofractionated whole breast external beam radiotherapy - have their respective merits and drawbacks, and this article attempts to dissect the issue.en_US
dc.description.affiliationDepartment of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India. anusheel8@hotmail.comen_US
dc.identifier.citationMunshi A. External hypofractionated whole-breast radiotherapy: now where does accelerated partial breast irradiation stand? Journal of Cancer Research and Therapeutics. 2007 Oct-Dec; 3(4): 231-5en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/111562
dc.language.isoengen_US
dc.source.urihttps://www.cancerjournal.neten_US
dc.subject.meshBreast Neoplasms --radiotherapyen_US
dc.subject.meshDose Fractionationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshRadiotherapy, Adjuvanten_US
dc.titleExternal hypofractionated whole-breast radiotherapy: now where does accelerated partial breast irradiation stand?en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Cancer Research and Therapeutics